secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001193125-26-201408
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve reverse split range, authorized share reduction, equity plan amendments via written consent
--------------------------------------------------------------------------------

- Ratified amendment to 2018 Equity Plan: shares available increased to 20M, ISO limit to 30M.
- Approved restated plan extending ISO grant period, further raising ISO limit, extending evergreen provision.
- Approved reverse stock split at ratio 1:2 to 1:20, with board discretion for up to one year.
- Approved decrease in authorized common shares from 500M to 100M, effective at board discretion within one year.
- Votes cast by 4,324,964 shares (57.1% of outstanding) on April 28, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000119312526201408/0001193125-26-201408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000119312526201408/d151139d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-201408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer